Arrhythmia Research (HRT) Q1 Profit Slips Amid Stronger Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HRT Hot Sheet
Price: $14.36 --0%
Financial Fact:
Selling and marketing: 303.28K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Selling and marketing: 303.28K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Arrhythmia Research Technology, Inc. (NYSE: HRT) reported Q1 EPS of $0.01, versus $0.04 reported last year. Revenue for the quarter came in at $6.18 million, versus $5.59 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
